Medigene

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Medigene has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last year, Medigene had revenue of €6.03M and net profit of -€16.18M

(EUR)	2023	YoY
Revenue	6.03M	80.69%
Gross profit	4.39M	40.76%
Net profit	-16.18M	94.20%
EBITDA	-14.59M	211.23%

Fundamentals

Metric	Value
Market capitalization	€1.18M
Number of shares	13.1M
52-week high/low	€2.25 - €0.0804
Dividends	No
Beta	1.40
P/E ratio	-0.10
PEG ratio	0.00
P/B ratio	0.08
P/S ratio	0.33

Company profile

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.